Swiger KJ - Search Results

1

Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention?

Swiger KJ, Singh J, Lenihan DJ. Swiger KJ, et al. Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):20. doi: 10.1007/s11936-017-0517-7. Curr Treat Options Cardiovasc Med. 2017. PMID: 28299613 Review.

2

Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.

Swiger KJ, Friedman EA, Brittain EL, Tomasek KA, Huang S, Su YR, Sawyer DB, Lenihan DJ. Swiger KJ, et al. Amyloid. 2016 Dec;23(4):242-248. doi: 10.1080/13506129.2016.1242480. Epub 2016 Nov 4. Amyloid. 2016. PMID: 27809600

3

Potential impact of cardiology phone-consultation for patients risk-stratified by the HEART pathway.

Monahan K, Pan M, Opara C, Yiadom MYAB, Munoz D, Holmes BB, Stephen D, Swiger KJ, Collins SP. Monahan K, et al. Among authors: swiger kj. Clin Exp Emerg Med. 2019 Sep;6(3):196-203. doi: 10.15441/ceem.18.066. Epub 2019 Jul 12. Clin Exp Emerg Med. 2019. PMID: 31295990 Free PMC article.

4

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.

Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. Dahagam C, et al. Among authors: swiger kj. Future Cardiol. 2016 Mar;12(2):139-48. doi: 10.2217/fca.15.89. Epub 2016 Feb 25. Future Cardiol. 2016. PMID: 26911578 Review.

5

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.

Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. Dahagam C, et al. Among authors: swiger kj. Future Cardiol. 2016 Mar;12(2):149-57. doi: 10.2217/fca.15.88. Epub 2016 Feb 25. Future Cardiol. 2016. PMID: 26911710 Review.

6

Cholesterol, statins, and dementia: what the cardiologist should know.

Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Wanamaker BL, et al. Among authors: swiger kj. Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13. Clin Cardiol. 2015. PMID: 25869997 Free PMC article. Review.

7

PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.

Swiger KJ, Martin SS. Swiger KJ, et al. Drug Saf. 2015 Jun;38(6):519-26. doi: 10.1007/s40264-015-0296-6. Drug Saf. 2015. PMID: 25989944

8

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects.

Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Swiger KJ, et al. Mayo Clin Proc. 2013 Nov;88(11):1213-21. doi: 10.1016/j.mayocp.2013.07.013. Epub 2013 Oct 1. Mayo Clin Proc. 2013. PMID: 24095248 Review.

9

Very large database of lipids: rationale and design.

Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR. Martin SS, et al. Among authors: swiger kj. Clin Cardiol. 2013 Nov;36(11):641-8. doi: 10.1002/clc.22214. Epub 2013 Oct 1. Clin Cardiol. 2013. PMID: 24122913 Free PMC article.

10

Impact on cognitive function-are all statins the same?

Shah NP, Swiger KJ, Martin SS. Shah NP, et al. Among authors: swiger kj. Curr Atheroscler Rep. 2015 Jan;17(1):466. doi: 10.1007/s11883-014-0466-5. Curr Atheroscler Rep. 2015. PMID: 25398642 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page